Evidence map›Paper›PMID 39212998›Full record

ArticleJournal of clinical gastroenterology2025

Noninvasive Disease Assessment in Eosinophilic Esophagitis With Fractionated Exhaled Nitric Oxide, Blood, and Fecal Biomarkers.

Andreas Göldi, Tanay Kaymak, Luca Esposito, Anouk Lehmann, Simona Negoias, Michael Tamm, Jan Hendrik Niess, Petr Hruz

Abstract read
In one paragraph

Article in Journal of clinical gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Shifting the scope: Moving toward less invasive diagnosis and monitoring of eosinophilic esophagitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Review
  3. Emerging Tissue and Blood Biomarkers for Eosinophilic Esophagitis.Gastroenterology clinics of North America · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreas GöldiUniversity Digestive Healthcare Center, Clarunis.
Tanay KaymakUniversity Digestive Healthcare Center, Clarunis.
Luca EspositoUniversity Digestive Healthcare Center, Clarunis.
Anouk LehmannUniversity Digestive Healthcare Center, Clarunis.
Simona NegoiasDepartment of Otorhinolaryngology, University Hospital of Basel.
Michael TammClinic of Respiratory Medicine, University Hospital Basel, Basel, Switzerland.
Jan Hendrik NiessUniversity Digestive Healthcare Center, Clarunis.
Petr HruzUniversity Digestive Healthcare Center, Clarunis.ORCID 0000-0003-2767-0445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus triggered by food and aeroallergens. There is a need for noninvasive biomarkers that reliably detect EoE in patients with cardinal symptoms and predict treatment response to reduce endoscopic evaluations. STUDY: Nonasthmatic patients 18 years or above with suspected or diagnosed EoE, gastroesophageal reflux disease (GERD), and control individuals with indication for endoscopy were enrolled prospectively between November 2020 and May 2022. Participants underwent body plethysmography with fractionated exhaled nitric oxide (FeNO) level measurement. Besides, serum and fecal biomarkers were measured by ELISA. A follow-up examination was scheduled after treatment initiation in patients with active EoE.

resultsThe median FeNO level in active EoE (20 ppb) was higher compared with GERD (15 ppb, P =0.038) and control individuals (14 ppb, P =0.046). Median FeNO did not significantly differ in EoE patients who underwent follow-up assessment after treatment response (20 ppb vs. 18 ppb, P =0.771). Serum EDN, ECP, and the absolute eosinophil blood count (AEC) were elevated in active EoE compared with control individuals but not compared with GERD except for AEC. Serum EDN, ECP and AEC decreased in EoE in remission at follow-up assessment. None of the fecal biomarkers was elevated in active EoE or during treatment.

conclusionsAssessment of FeNO may have diagnostic value in differentiating patients with active EoE from non-EoE patients but is not a suitable marker for monitoring disease activity. Serum EDN, ECP, TARC, and AEC levels are emerging as potential candidates for monitoring disease activity in EoE.

Indexed as

Eosinophilic EsophagitisFecesFractional Exhaled Nitric Oxide TestingNitric OxideAdultBiomarkersEosinophil Cationic ProteinEosinophil-Derived NeurotoxinEosinophilsFemaleGastroesophageal RefluxHumansLeukocyte CountMaleMiddle AgedProspective StudiesBiomarkersEosinophil Cationic ProteinEosinophil-Derived NeurotoxinNitric OxidebiomarkerECPEDNeosinophilic esophagitisFeNO

Identifiers

PMID39212998
PMCPMC12329813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.